Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single ascending dose study evaluating the safety and tolerability of POL6014 in individuals with cystic fibrosis

Trial Profile

A single ascending dose study evaluating the safety and tolerability of POL6014 in individuals with cystic fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs POL 6014 (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Oct 2018 Status changed from recruiting to completed, according to a Santhera Pharmaceuticals media release.
    • 24 Oct 2018 According to a Santhera Pharmaceuticals media release, data been presented at the North American Cystic Fibrosis Conference in October 2018.
    • 24 Oct 2018 According to a Santhera Pharmaceuticals media release, the Cystic Fibrosis Foundation (CFF) is providing funding support for the conduct of the safety trials with POL6014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top